🇺🇸 FDA

Company profile · Sponsor

Toray

Toray International U.K. Limited

EABB656 · EMA pharma GB
Pipeline
1
Drugs
0
Patents
0

Quick answer

Toray (EABB656) is a pharma company. headquartered in GB. listed on EMA. NovaPharmaNews links 1 pipeline program, 0 drugs, and 0 patents to this profile..

Company facts

Ticker EABB656
Exchange EMA
Company type pharma
Headquarters GB

Pipeline (1)

Search pipeline →

  1. A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors

    Toray

    Bladder cancer, Cholangiocarcinoma, Colorectal Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Gastric Cancer, Melanoma, Ovarian Cancer, Palpable Subcutaneous Malignant Lesions, Primary Peritoneal Cancer, Renal Cell Carcinoma, Solid Tumor

    phase 1 other active

    1 trial

Frequently asked questions

What is Toray?

Toray (EABB656) is a pharma company. headquartered in GB. listed on EMA. NovaPharmaNews links 1 pipeline program, 0 drugs, and 0 patents to this profile..

What pipeline programs does Toray sponsor?

We track 1 ClinicalTrials.gov-linked program for Toray, including A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors. Open each program for phase, modality, NCT IDs, and indication details.

Where does Toray company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.